Alzheimer's Disease: Phase II Gammagard Findings
Alzheimer's drug IVIg could halt sufferers' decline
Trial involving 16 patients excites scientists by suggesting treatment prevented deterioration of memory and cognitive skills
Alexandra Topping and agencies
Wednesday 18 July 2012 10.21 BST
"A new treatment for Alzheimer's could halt deterioration in people with early symptoms of the disease, a limited human trial has shown. The treatment, called the "most exciting drug in development" by scientists, is currently prescribed to people with immune system problems but could have a significant impact on the quality of life of Alzheimer's sufferers, the trial suggests.
"The drug, intravenous immunoglobulin (IVIg), prevented the decline in cognitive skills, memory and the ability to live independently, among patients with mild to moderate symptoms of Alzheimer's. Those who took a placebo continued to decline. The small number of patients who took the highest dose of the drug for three years showed no decline in memory."
Here is the AAIC press release: Read the AAIC press release